SCHEMBL22862551

SCHEMBL22862551

Cn1c(=O)n(C)c2cc(CCl)ccc21

nearest known ligand 0.53

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ POLB P06746 2/20 0.53
▸ SMN1; SMN2 Q16637 5/20 0.51
▸ ALDH1A1 P00352 5/20 0.51
▸ LMNA P02545 1/20 0.51
▸ HTT P42858 1/20 0.51
▸ TSHR P16473 1/20 0.48
▸ L3MBTL1 Q9Y468 1/20 0.48
▸ BRD4 O60885 2/20 0.47
▸ BRPF1 P55201 2/20 0.47
▸ HSD17B10 Q99714 2/20 0.47
▸ KDM4E B2RXH2 2/20 0.47
▸ THRB P10828 2/20 0.46
▸ TP53 P04637 2/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ MEN1 O00255 1/20 0.44
▸ MAPT P10636 1/20 0.44
▸ KMT2A Q03164 1/20 0.44
▸ GLA P06280 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29490174 1.00 POLB (0.53) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL29490252 0.82 POLB (0.54) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL22862558 0.82 POLB (0.54) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL12136691 0.82 RAB9A (0.57) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL13156353 0.81 POLB (0.53) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL9388512 0.81 POLB (0.53) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL7479892 0.81 POLB (0.53) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL10208756 0.80 POLB (0.60) POLBSMN1; SMN2ALDH1A1LMNAHTT
Hydrochloric Acid SCHEMBL31737865 0.79 POLB (0.51) POLBSMN1; SMN2ALDH1A1LMNAHTT
SCHEMBL26014841 0.79 POLB (0.51) POLBSMN1; SMN2ALDH1A1LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023154310-A1 2-METHYL-4-PHENYLPIPERIDIN-4-OL DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME VERTEX PHARMACEUTICALS INCORPORATED (US) 2023-08-17 — — WO disclosed
US-20220389028-A1 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIVERSITY 2022-12-08 — — US disclosed
WO-2021002986-A2 BAX INHIBITORS AND USES THEREOF CASE WESTERN RESERVE UNIVERSITY (US) 2021-01-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389028-A1 BAX INHIBITORS AND USES THEREOF BAX, TMBIM6, BCL2 POLB 1716/4885SMN1; SMN2 2633/4885ALDH1A1 4296/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback